Clinical Outcomes in Patients with Cardiac Lupus: A Retrospective Study

Turaka, VijayPrakash; Koshy, KMaria; George, Tarun K; Das, Sohini; Punitha, J.V.; Rajan, SudhaJasmine; Yadav, Bijesh; Sudarsanam, ThambuDavid

doi:10.4103/injr.injr_127_19

Cited by 1 publication

(10 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average age of the majority of the study population fluctuated between 28.4 and 47.6 years old, and the percentage of females in the total study ranged from approximately 79.1%–93.9%. Eight studies were performed in Asia, 14,20,21,24–26,29,33 six in Europe, 18,19,22,30–32 and seven in the Americas. 7,9,11,13,23,27,28 Patients in 14 studies were treated with HCQ alone, 7,13,20–26,28,30–33 while patients in another 7 studies were treated with HCQ/CQ.…”

Section: Resultsmentioning

confidence: 99%

“…Twenty-one studies were included in the final meta-analysis. 7,9,11,13,14,[18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]…”

Section: Literature Search and Study Selectionmentioning

confidence: 99%

“…14 The publication year ranged from 2006 to 2022, with 7 prospective 9,11,13,19,21,22,26 and 14 retrospective cohort studies. 7,14,18,20,[23][24][25][27][28][29][30][31][32][33] The pooled patient population was 26,037, with the population of individual studies ranging from 51 to 4,575 participants. The average age of the majority of the study population fluctuated between 28.4 and 47.6 years old, and the percentage of females in the total study ranged from approximately 79.1%-93.9%.…”

Section: Study Characteristics and Quality Assessmentmentioning

confidence: 99%

“…Eight studies were performed in Asia, 14,20,21,[24][25][26]29,33 six in Europe, 18,19,22,[30][31][32] and seven in the Americas. 7,9,11,13,23,27,28 Patients in 14 studies were treated with HCQ alone, 7,13,[20][21][22][23][24][25][26]28,[30][31][32][33] while patients in another 7 studies were treated with HCQ/ CQ.…”

Section: Study Characteristics and Quality Assessmentmentioning

confidence: 99%

“…14,15 In these cohort studies, HCQ not only had a protective effect against accrual damage 16 but was also associated with a shorter hospital stay 17 . More notably, HCQ has been shown to be associated with extended survival in SLE [18][19][20][21][22][23][24][25][26][27][28] in spite of some contrary results. [29][30][31][32][33] Consequently, given the inconsistencies in the above studies and a wide range of adverse effects of HCQ, there is still no definite conclusion that HCQ use can reduce mortality risk in SLE patients.…”

Section: Introductionmentioning

confidence: 98%

See 4 more Smart Citations

Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies

Cai

Zhao

Yanping

et al. 2022

Lupus

View full text Add to dashboard Cite

Objective Hydroxychloroquine (HCQ) is widely used in patients with systemic lupus erythematosus (SLE), but its effects on the mortality have not reached a definite conclusion. In this systematic review and meta-analysis, we aimed to assess whether HCQ use could reduce the risk of mortality in SLE patients. Methods PubMed, Embase, Web of Science, and Cochrane database were searched from inception to April 17, 2022 without language restrictions to explore the relationship between HCQ use and SLE mortality. The relative risk (HR) was pooled using the STATA software. Results A total of 21 studies with a pooled patient population of 26,037 were included in the study, including 14 studies on the association between HCQ alone and mortality risk and seven studies on the association between HCQ/chloroquine (CQ) and mortality risk. The pooled findings suggested that HCQ significantly reduced the overall mortality risk of SLE (pooled HR 0.46, 95% CI 0.38–0.57, p < 0.001). In subgroup analysis of SLE complications, HCQ use also decreased the risk of death in SLE patients with renal (HR=0.43, 95% CI 0.26–0.70, p = 0.001) and cardiopulmonary involvement (HR=0.37, 95% CI= 0.25–0.54, p < 0.001). In addition, HCQ use was also protective against the risk of mortality in SLE patients in different regions, such as Asia (HR=0.46, 95% CI=0.33–0.64, p < 0.001), Europe (HR= 0.40, 95% CI = 0.22–0.71, p = 0.002), and America (HR=0.52, 95% CI= 0.42–0.64, p < 0.001). Conclusion Our data suggested that HCQ use was associated with a reduced risk of mortality in patients with SLE.

show abstract